ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2025
[Clinical features and prognosis of sarcoidosis with ocular lesions as the initial manifestation].
Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical features of sarcoidosis with ocular lesions as the initial manifestation and to analyze its treatment and prognostic outcomes.
methodsA retrospective study was conducted to evaluate the clinical data of sarcoidosis patients from July 2010 to July 2025 in the Department of Rheumatology and Immunology, Beijing Tongren Hospital.
resultsAmong the 23 patients, the male-to-female ratio was 1 ∶ 2.3, with a mean age of (45.1±14.1) years, a median disease duration of 0.5 (0.25, 1.50) years, and a median diagnosis time of 0.5 (0.20, 1.00) years. Fourteen patients presented with ocular lesions as the initial manifestations, while 9 patients had non-ocular lesions (such as respiratory system involvement or joint swelling/pain) as the initial manifestations. The most common ocular lesions were non-infectious uveitis and orbital masses. Orbital masses were most commonly encountered as lacrimal gland enlargement. Other ocular lesions included optic neuritis and optic perineuritis. The median follow-up time was 21.21 (5.00, 147.29) months. Following treatment, all the patients achieved significant clinical improvement, of whom 3 patients with non-infectious uveitis and 1 with optic perineuritis showed improved visual acuity and overall visual function. During the follow-up period, 2 patients with sarcoidosis experienced disease recurrence. After their treatment regimens were reinitiated, both patients achieved remission with a favorable prognosis. Compared with the patients with non-ocular-onset as the initial manifestation, the patients with ocular-onset as the initial manifestation had a significantly longer diagnosis time, and the difference was statistically significant (
conclusionSarcoidosis with ocular-onset as the initial manifestation poses diagnostic challenges, as routine inflammatory markers have limited utility in suggesting the disease and thus it is easily overlooked. Therefore, enhancing clinicians' ability to recognize these ocular-onset features is crucial for achieving early diagnosis and enabling timely intervention.
Indexed as
Identifiers
41399066PMC12711423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.